ArticlePloS one2025
Evaluation of Streptococcus pneumoniae as a cause of acute otitis media in Colombia: A prospective study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSince the introduction of the pneumococcal conjugate vaccine PCV-10 in 2011 its impact on acute otitis media (AOM) in children under five years of age in Colombia was unknown. We aimed to describe the clinical and sociodemographic characteristics of a prospective cohort of patients between 3 and 59 months old attending a children's hospital in Cartagena, Colombia.
methodsA prospective cohort study was conducted over a 12-month period from August 5th, 2022 to August 5th, 2023. Diagnosis of AOM was confirmed by an otorhinolaryngologist. Middle ear fluid samples were obtained by swab or tympanocentesis, depending on the presence of spontaneous drainage. Samples with a positive culture for S. pneumoniae were sent to the Colombian National Health Institute for serotyping. We also estimated the prevalence of AOM caused by S. pneumoniae, the serotype distribution and antimicrobial resistance patterns.
resultsA total of 61 patients were enrolled, 58% were male, the median age was 12 months (IQR: 8-24). The most common isolated microorganisms were Pseudomonas aeruginosa (14.8%), methicillin-resistant Staphylococcus aureus (13.1%), and Streptococcus pneumoniae (9,8%). Six cases of S. pneumoniae were identified, median age was 26.5 months (IQR: 8-45), none had any comorbidities, and only one had a history of previous AOM episodes. Five of them were vaccinated. The serotype distribution was 19A (67%), 10F and 35A (17%) each. Within the antimicrobial resistance patterns, serotype 19A was multidrug resistant (resistance to: beta-lactams, macrolides, lincosamides and TMP/SMX).
conclusionS. pneumoniae continues to be a leading cause of AOM in our country. Serotype 19A accounts for 67% of these infections and exhibits a multidrug-resistant pattern similar to that observed in invasive pneumococcal disease. These findings are consistent with international data and provide a baseline for tracking future AOM trends related to S. pneumoniae after the introduction of the PCV-13 vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.